Product NDC: | 61703-304 |
Proprietary Name: | Cytarabine |
Non Proprietary Name: | CYTARABINE |
Active Ingredient(s): | 20 mg/mL & nbsp; CYTARABINE |
Administration Route(s): | INTRAVENOUS; SUBCUTANEOUS |
Dosage Form(s): | SOLUTION |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 61703-304 |
Labeler Name: | Hospira Worldwide, Inc. |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | ANDA072945 |
Marketing Category: | ANDA |
Start Marketing Date: | 19940228 |
Package NDC: | 61703-304-36 |
Package Description: | 1 VIAL, MULTI-DOSE in 1 CARTON (61703-304-36) > 25 mL in 1 VIAL, MULTI-DOSE |
NDC Code | 61703-304-36 |
Proprietary Name | Cytarabine |
Package Description | 1 VIAL, MULTI-DOSE in 1 CARTON (61703-304-36) > 25 mL in 1 VIAL, MULTI-DOSE |
Product NDC | 61703-304 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | CYTARABINE |
Dosage Form Name | SOLUTION |
Route Name | INTRAVENOUS; SUBCUTANEOUS |
Start Marketing Date | 19940228 |
Marketing Category Name | ANDA |
Labeler Name | Hospira Worldwide, Inc. |
Substance Name | CYTARABINE |
Strength Number | 20 |
Strength Unit | mg/mL |
Pharmaceutical Classes | Nucleic Acid Synthesis Inhibitors [MoA],Nucleoside Metabolic Inhibitor [EPC] |